Worldwide, Pseudomonas aeruginosa remains a leading nosocomial pathogen that is
difficult to treat and constitutes a challenging menace to healthcare systems. P. aeruginosa …

Objective The emergence of resistance to colistin, the last resort for treating severe
infections caused by Pseudomonas aeruginosa, poses a significant threat to public health …

Increasing rates of serious multi-drug resistant (MDR) Pseudomonas aeruginosa infections
have been reported globally, including in Saudi Arabia. This retrospective study investigates …

Among consecutive patients with multidrug-resistant Pseudomonas aeruginosa bacteremia
or pneumonia we found those treated with ceftazidime-avibactam were more likely to …

Background Ceftolozane–tazobactam and ceftazidime–avibactam are preferred treatment
options for multidrug-resistant Pseudomonas aeruginosa infections; however, real-world …

Ceftolozane-tazobactam (CT) and ceftazidime-avibactam (CAZ-AVI) are two novel
antimicrobials that retain activity against resistant Pseudomonas aeruginosa. The …

Background Antibiotics significantly increased life expectancy and decreased mortality rates
due to infections. However, this trend is starting to fade with the rise of multidrug-resistant …

Pseudomonas aeruginosa is a ubiquitous opportunistic bacterium that causes diseases in
animals and humans. This study aimed to investigate the genetic diversity, antimicrobial …

Carbapenem-resistant Pseudomonas aeruginosa is defined by the World Health
Organization as a" high priority" in developing new antimicrobials. Indeed, the emergence …

Pseudomonas aeruginosa is one of the major infectious agents in burn patients. Globally,
high rates of antimicrobial resistance in P. aeruginosa have been reported, which is a cause …